PET RANO 1.0 criteria improve prognostic stratification in high-grade gliomas using 11C-methionine PET/MR
Journal of Neuro-Oncology · 2026
DOI: 10.1007/s11060-026-05429-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2026. Verfasst von Shih-Hsin Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Linkou Chang Gung Memorial Hospital, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan. Hauptthemen laut MEDLINE: Glioma, Positron-Emission Tomography, Magnetic Resonance Imaging, Brain Neoplasms. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital.
Abstract (Originalsprache)
PURPOSE: This study aimed to identify prognostic factors for survival outcomes in patients with high-grade gliomas (HGGs) using 11C-methionine positron emission tomography/magnetic resonance imaging (MET PET/MR) to evaluate tumor response following surgical resection and concurrent chemoradiotherapy (CCRT). METHODS: Twenty-nine patients with histologically confirmed grade 3 and 4 HGGs were enrolled between November 2019 and May 2022. All patients underwent baseline MET PET/MR scans within one month post-surgery, followed by standard Stupp protocol chemoradiotherapy. Twenty-three patients completed follow-up scans post-CCRT. Treatment response was evaluated using PET RANO 1.0 criteria for PET, and RANO 2.0 criteria for MRI. Prognostic factors were analyzed using Cox proportional hazards models. RESULTS: Among 23 patients evaluated post-CCRT, PET RANO 1.0 classified 18 as responders and 5 as non-responders. PET responders demonstrated significantly superior median progression-free survival (PFS) (22.4 vs. 4.0 months, P < 0.001) and overall survival (OS) (47.9 vs. 11.4 months, P < 0.001) compared with non-responders. Conversely, MRI RANO 2.0 criteria did not show statistically significant differences in survival outcomes (median PFS: 20.9 vs. 9.2 months, P = 0.510; median OS: 44.0 vs. 17.3 months, P = 0.902). Multivariate analysis confirmed MET PET response as an independent prognostic factor for both PFS and OS. CONCLUSIONS: MET PET response assessment based on PET RANO 1.0 criteria demonstrated potential prognostic utility, offering complementary information to conventional MRI-based assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Linkou Chang Gung Memorial Hospital, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan.
- School of Medicine, National Tsing Hua University, Hsinchu, Taiwan.
- Department of Nuclear Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan.
- Department of Diagnostic Radiology and Intervention, Linkou Chang Gung Memorial Hospital and Chang Gung University, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan.
- Department of Neurosurgery, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.
- Department of Neurosurgery and Neuroscience Research Center, Linkou Chang Gung Memorial Hospital and Chang Gung University, No. 5, Fuxing Street, Gueishan Dist., Taoyuan, 33305, Taiwan.
Förderung
- Chang Gung Memorial Hospital
Zitieren
APA
Chen, S. H., Wang, H. N., Toh, C. H., Wei, K. C., Chen, K. T., Tseng, C. K., & Ho, K. C. (2026). PET RANO 1.0 criteria improve prognostic stratification in high-grade gliomas using 11C-methionine PET/MR. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-026-05429-2
Vancouver
Chen SH, Wang HN, Toh CH, Wei KC, Chen KT, Tseng CK, et al. PET RANO 1.0 criteria improve prognostic stratification in high-grade gliomas using 11C-methionine PET/MR. Journal of Neuro-Oncology. 2026. doi:10.1007/s11060-026-05429-2
BibTeX
@article{Chen2026,
author = {Chen, Shih-Hsin and Wang, Hsin-Ning and Toh, Cheng Hong and Wei, Kuo-Chen and Chen, Ko-Ting and Tseng, Chen-Kan and Ho, Kung-Chu},
title = {PET RANO 1.0 criteria improve prognostic stratification in high-grade gliomas using 11C-methionine PET/MR},
journal = {Journal of Neuro-Oncology},
year = {2026},
doi = {10.1007/s11060-026-05429-2}
}
EUVIMED